IL-15 R alpha Molekülinformation
Molecule Name
Interleukin-15 receptor subunit alpha
Molekülalias
IL-15 R alpha,CD215,IL15RA,IL-15RA,IL-15R-alpha
Drug Development Progress
Anzahl der klinischen Arzneimittel13
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Target-Alias
Interleukin 15 Receptor Alpha Isoform IC2，Interleukin 15 Receptor Alpha Isoform IC8，Interleukin 15 Receptor Alpha Isoform EM2，Interleukin-15 Receptor Subunit Alpha，Interleukin 15 Receptor Alpha Isoform IC4，Interleukin 15 Receptor Alpha Isoform IC5，Interleukin 15 Receptor Alpha Isoform IC7，IL15RA，CD215，IL-15RA，IL-15 Receptor Subunit Alpha，CD215 Antigen，Interleukin 15 Receptor Subunit Alpha，Interleukin 15 Receptor Alpha Isoform IC6，Interleukin 15 Receptor， Alpha，Interleukin 15 Receptor Alpha Isoform IC3，sIL-15 receptor subunit alpha，IL-15R-Alpha，Interleukin-15 Receptor alpha Subunit，sIL-15RA，sIL-15R-alpha
Molekülhintergrund
IL15R is a heterotrimer of IL15RA, IL2RB and IL2RG. IL-15RA, also known as CD215, IL-15 R alpha, is a widely expressed 60 kDa transmembrane glycoprotein. High-affinity receptor for interleukin-15. Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. Expression of different isoforms may alter or interfere with signal transduction. An interleukin (IL)-15 superagonist/IL-15 receptor α fusion complex (IL-15SA/IL-15RA; ALT-803) activates the IL-15 receptor on CD8 T cells and NK cells, and has shown significant anti-tumor. Signal transduction involves SYK. Higher levels of soluble sIL-15RA form in comparison with membrane-bound forms is present in all brain structures.
IL-15 R alpha Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| SHR-1501 | SHR-1501 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms; Urinary Bladder Neoplasms | Details |
| Avipendekin pegol | NKTR-255 | Phase 2 Clinical | Nektar Therapeutics | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck | Details |
| ASKG-915 | ASKG-915 | Phase 2 Clinical | Askgene Pharma | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| VG-201 | VG-201 | Phase 2 Clinical | ViroGin Biotech Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| FL115 | FL-115; FL115 | Phase 2 Clinical | Suzhou Forlongbiotech Co Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
| Efbalropendekin alfa | XmAb-24306; RG-6323; RO-7310729; XmAb-306 | Phase 1 Clinical | Xencor Inc | Multiple Myeloma; Solid tumours | Details |
| BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Communicable Diseases; Neoplasm Metastasis; Solid tumours | Details |
| ASKG-315 | ASKG-315; ASKG-215b; ASKG-215β | Phase 1 Clinical | Askgene Pharma | Neoplasms; Solid tumours | Details |
| VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | Fenojian Biotechnology (Nantong) Co Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, ViroGin Biotech Ltd | Breast Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Solid tumours | Details |
| BAT-7205 | BAT7205; BAT-7205 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Neoplasm Metastasis; Solid tumours | Details |
| RC-198 | RC-198 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details |